The Gatherer Vol 11

James Wiliams, Dimerix Chairman & Co-Founder Dimerix is a great example of a biopharmaceutical company with origins in Perth. It’s now progressing to later stage clinical trials for diseases that affect millions of people around the world. Jayden Rogers, Linear Clinical Research CEO The demand for clinical trials in Australia has been at an all-time high for the last three years. This is on the back of our world-class healthcare system, a pragmatic regulatory environment and cost advantages, particularly relative to the US and Europe. Liddy McCall, Yuuwa Capital Investment Director & Dimerix Co-Founder The Perth community and the biotech community is very interested in what’s happening, and the fact that we’ve created successes from Australian innovation that now are commercially available drugs. The more we do of that, the more we benefit Western Australia and Perth as a biotech hub. Kevin Pfleger, UWA Director Biomedical Innovation & Dimerix Chief Scientific Advisor We should be very proud of our universities and our medical research institutes in WA. We have achieved many innovations which have gone global, including five FDA approved drugs that have come out of our institutions. Todd Shand, Wrays Principal The ability to reverse engineer a small molecule pharmaceutical is something that pharmaceutical companies have to deal with all the time. It’s relatively easy for a company to look at what Dimerix has done and produce it cheaply as they don’t have to conduct all the research and development. It’s just a straight-up copy. The importance of intellectual property is that it’s the only barrier that stops that from happening.

W estern Australia is filled with incredible innovation success, especially in the life sciences sector. A celebrated example of such success is Dimerix - a biopharmaceutical company with origins in Perth, now experiencing global reach. Dimerix is responsible for developing DMX-200, a small molecule drug used for the treatment of chronic kidney disease. Currently in phase-3 clinical trials, we’re excited to share more of this ongoing success story. HOMEGROWN WORLD-CLASS INNOVATION SUCCESS We explore Dimerix’s commercialisation journey

Formulated as a capsule to be taken twice a day, DMX-200 is a small chemical compound developed to treat underlying conditions that involve inflammation. Initially, the drug has been used to treat chronic kidney disease, which affects an estimated 10% of Australian adults. Later-stage clinical trials are now progressing for other inflammation-related diseases that affect millions of people around the world. To reach this stage of the commercialisation journey, the team at Dimerix have worked in close collaboration with innovative minds from Linear Clinical Research, Yuuwa Capital, the University of WA and Wrays. Here’s what the project team had to say.

To view the full video visit wrays.com.au/insights/dimerix

wrays . com.au | 31